Risk reduction with long-term clopidogrel following percutaneous coronary intervention

Steven R. Steinhubla,* and Eric J. Topola,b

a Division of Cardiology, University of Kentucky, Lexington KY, USA
b Division of Cardiology Cleveland Clinic Foundation, Cleveland, OH, USA

Received July 30, 2004; revised July 30, 2004; accepted August 6, 2004 * Corresponding author. Present address: Division of Cardiovascular Medicine, University of Kentucky, 900 S. Limestone Strret, 326 Charles T. Weddington Bulding, Lexington, KY 40536-0284, USA. Tel.: +859 323 8040; fax: +859 323 6475 (E-mail: Steinhubl{at}uky.edu).

Only recently have we begun to appreciate that the mechanical treatment of a haemodynamically significant coronary lesion does not represent conclusive therapy for atherosclerotic disease, but rather serves as a warning for a heightened risk of future events and the need for aggressive preventative therapies. A recently published analysis attempted to quantify the benefit of long-term clopidogrel therapy in such patients.1 We do not feel the conclusions of the author are supported when the results from the CREDO trial and the subset analysis of PCI patients from the CURE trial are accurately analysed.

PCI-CURE was a pre-specified observational subset analysis of the much larger CURE trial.2 When these results are interpreted as they were intended, as part of the overall CURE trial, the key finding was that the long-term benefit of clopidogrel seen in CURE (from day 30 to end of follow-up, 0.82 relative risk in death/ myocardial infarction (MI) or stroke, 95% CI 0.70–0.95, p=0.009) was the same whether the patient underwent a PCI or not.3 This significant risk reduction seen in the entire CURE cohort between 30 days and the end of follow-up is very similar to the 0.79 relative risk of death and MI reported in the PCI-CURE manuscript, and not the 14% "maximal conceivable effect" reported in the Opinion paper.1

CREDO was a blinded, placebo-controlled trial powered to identify the benefit of clopidogrel pretreatment plus long-term therapy in patients undergoing a planned PCI, or at high likelihood to undergo a PCI, on the 1-year combined incidence of death, MI and stroke.4 Although not designed to show a significant benefit between day 29 and 1 year, a statistically significant 37% relative risk reduction, 1.9% absolute risk reduction was observed. (Fig. 1) While it is true that without re-randomization at day 29 it is impossible to separate the benefit of pretreatment and long-term therapy with 100% certainty, it is difficult to hypothesise a mechanism for pretreatment preventing late deaths, as well as MIs and strokes up to a year after a PCI. Contrary to the assertion in the Eriksson paper, data from the placebo-controlled abciximab trials have found an influence on late mortality alone.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1 Kaplan–Meier estimates of death, myocardial infarction or stroke from day 29 to 1 year based on randomized treatment assignment in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

 
Finally, the benefits of adding clopidogrel long-term after PCI should be interpreted in the context of other proven therapies. Table 1 summarizes the absolute and relative benefits that have been described for similar populations through placebo-controlled trials of aspirin, statins and ACE-inhibitors. Unfortunately, with no trial data yet available beyond only 1 year of follow-up for clopidogrel and aspirin versus aspirin alone, and with the event curves separating at the end of follow-up in both trials, it is difficult to speculate what the actual benefit of life-long therapy might be, but the available data suggests that it is likely to be even greater than for other accepted therapies. The actual benefit awaits the results of the CHARISMA trial.


View this table:
[in this window]
[in a new window]
 
Table 1. Reduction in death, myocardial infarction and stroke with long-term preventative therapies
 

References

  1. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the Emperor's New Clothes revisited Eur Heart J 2004;25:720-722.[Free Full Text]
  2. Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undrgoing percutaneous coronary intervention: The PCI-CURE study Lancet 2001;358:527-533.[CrossRef][ISI][Medline]
  3. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes Circulation 2003;107:966-972.[Abstract/Free Full Text]
  4. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial JAMA 2002;288:2411-2420.[Abstract/Free Full Text]
  5. Antithrombotic Trialists C Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002;324(7329):71-86[erratum appears in BMJ 2002 Jan 19;324(7330):141].[Abstract/Free Full Text]
  6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000;342:145–53.
  7. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial JAMA 2002;287:3215-3222.[Abstract/Free Full Text]




This Article
Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Request Permissions
Google Scholar
Articles by Steinhubl, S. R.
Articles by Topol, E. J.
PubMed
PubMed Citation
Articles by Steinhubl, S. R.
Articles by Topol, E. J.